跳至主要内容
临床试验/NCT03488212
NCT03488212Unknown不适用

Pragmatic Trial of Technology-Supported Behavioral Obesity Treatment in the Primary Care Setting: A Multiphase Effectiveness and Implementation Hybrid Design

The Miriam Hospital2 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2018年5月31日最近更新:
适应症

试验速览

阶段
不适用
入组人数
600
试验地点
2
主要终点
Change in Weight

研究概览

简要总结

Behavioral obesity treatment produces clinically significant weight loss; for the greatest impact, it should be made available in the primary care setting where it can reach the many patients with overweight/obesity. The investigators developed a 3-month automated online behavioral weight loss program, Rx Weight Loss (RxWL), and showed that it produces clinically significant weight losses among primary care patients. The investigators' early efforts at pragmatic implementation of RxWL have been promising, and have shed light on challenges associated with implementation, and the need to study longer-term effectiveness. The investigators will therefore conduct a pragmatic study to improve the implementation and effectiveness of this behavioral obesity intervention delivered in routine and representative healthcare settings. The investigators are partnering with the Rhode Island Primary Care Physicians Corporation (RIPCPC), a large primary care network of 58 practices with 100 physicians and 16 nurse care managers. Using the framework for Effectiveness-Implementation Hybrid Designs, the investigators will simultaneously target effectiveness and implementation to maximize the public health impact of the research. Half of the 16 nurse care managers, and the practices they serve, will be randomized to either Basic Implementation (alerts generated using the electronic medical record [EMR] to direct eligible patients to RxWL), or to the Enhanced Implementation (alerts, clinician skills training to motivate and support weight loss, clinician dashboard with reports on patient progress and tools to facilitate patient engagement and behavior change). The investigators will test the hypothesis that the Enhanced Implementation will increase the proportion of patients directed to, enrolling, and completing the weight loss program. Because maintenance of weight loss is a critical problem, this project will also involve randomization of 600 patients with overweight/obesity and type 2 diabetes, hypertension, and/or hypercholesterolemia to the 3 month RxWL intervention followed by one of three maintenance conditions: (a) Control- 9 monthly online education sessions; (b) Monthly Lessons and Feedback- 9 monthly online video lessons teaching self-regulation with automated feedback on the self-monitoring record; (c) Refresher Campaigns- 9 monthly on-line video sessions, teaching self-regulation and providing two 4-week courses with novel strategies and behavioral challenges to improve long-term outcomes. The investigators will test the hypothesis that 12-month weight losses are better with Refresher Campaigns than Monthly Lessons and Feedback, and both are better than Control. Secondary outcomes include changes in weight, CVD risk factors, and medication use over a full 24 months. The project is significant and innovative because: it uses an empirically validated approach to obesity treatment that is integrated into the primary care setting, leveraging existing staff and EMR capabilities; it has a dual focus on improving effectiveness and implementation; it has a pragmatic design in partnership with a large primary care network that treats a diverse patient population; and it has potential to it provides a scalable, sustainable approach that can serve as a model for broader dissemination of obesity treatment intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Body mass index (BMI) between 25-45 kg/meters-squared
  • one or more cardiovascular risk factor (type 2 diabetes, hypercholesterolemia, or hypertension)

排除标准

  • currently in another active weight loss program
  • taking weight loss medication
  • currently pregnant, lactating
  • <6 months post-partum
  • plan to become pregnant during the next 12 months
  • a medical condition that would affect the safety of participating in unsupervised physical activity
  • inability to walk 2 blocks without stopping

结局指标

主要结局

Change in Weight

时间窗: 12 months after study enrollment

次要结局

  • Proportion of Patients Achieving a Weight Loss of ≥5% of Initial Body Weight(12 and 24 months after study enrollment)
  • Change in Low-density Lipoprotein (mg/dL)(12 and 24 months after study enrollment)
  • Change in Weight(24 months after study enrollment)
  • Provider Satisfaction with the Treatment Program(12 months after study enrollment)
  • Proportion of Patients Deemed Eligible by the Electronic Medical Record Who are Directed to the Online Treatment Program(24 months after study initiation)
  • Proportion of Enrolled Patients who Complete the Online Treatment Program(24 months after study initiation)
  • Patient Satisfaction with the Treatment Program(3 and 12 months after study enrollment)
  • Clinician Contact with Patients Directed to the Online Treatment Program(24 months after study initiation)
  • Patient Engagement and Adherence to the Online Intervention.(12 months after study enrollment)
  • Proportion of Patients That Enroll After Being Directed to the Online Treatment Program(24 months after study initiation)
  • Clinician Engagement with the Online Treatment Platform(24 months after study initiation)
  • Change in High-density Lipoprotein (mg/dL)(12 and 24 months after study enrollment)
  • Change in Triglycerides (mg/dL)(12 and 24 months after study enrollment)
  • Change in Systolic Blood Pressure (mmHG)(12 and 24 months after study enrollment)
  • Change in Blood Glucose (mg/dL)(12 and 24 months after study enrollment)
  • Change in Glycated Haemoglobin (HbA1c)(12 and 24 months after study enrollment)
  • Change in Diastolic Blood Pressure (mmHG)(12 and 24 months after study enrollment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

John Graham Thomas

Associate Professor (Research)

The Miriam Hospital

研究点 (2)

Loading locations...

相似试验